Rhabdomyolysis and acute renal failure due to combination therapy with simvastatin and warfarin

Journal of Internal Medicine

Volumn 246, Issue 6, 1999, Pages 599-602

  Mogyorósi, András ^a   Bradley, B ^a   Showalter, A ^a   Schubert, M L ^a  

^a VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Acute renal failure; Hyperkalaemia; Interaction; Rhabdomyolysis; Simvastatin; Warfarin

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; SIMVASTATIN; WARFARIN;

ACUTE KIDNEY FAILURE; AGED; ARTICLE; CASE REPORT; CREATINE KINASE BLOOD LEVEL; DRUG EFFECT; HUMAN; HYPERCHOLESTEROLEMIA; HYPERKALEMIA; MALE; PRIORITY JOURNAL; RHABDOMYOLYSIS;

AGED; AGED, 80 AND OVER; ANTICOAGULANTS; CREATINE KINASE; DRUG INTERACTIONS; HUMANS; HYDROXYMETHYLGLUTARYL COA REDUCTASES; KIDNEY FAILURE, ACUTE; MALE; RHABDOMYOLYSIS; SIMVASTATIN; WARFARIN;

EID: 0033406334     PISSN: 09546820     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2796.1999.00610.x     Document Type: Article

References (19)

1. 1 Boccuzzi SJ, Bocanegra TS, Walker JF, Shapiro DR, Keegan ME. Long-term safety and efficacy profile of simvastatin. Am J Cardiol 1991; 68: 1127-31.
2. 2 Ayanian JZ. Fuchs CS, Stone RM. Lovastatin and rhabdomyolysis (letter). Ann Intern Med 1988; 109: 682-83.
3. 3 Corpier CL, Jones PH, Suki WN et al. Rhabdomyolysis and renal injury with lovastatin use. Report of two cases in cardiac transplant recipients. J Am Med Assoc 1988; 260: 239-41.
4. 4 Goldman JA, Fishman AB, Lee JE, Johnson RJ. The role of cholesterol-lowering agents in drug-induced rhabdomyolysis and polymyositis (letter). Arthritis Rheum 1989; 32: 358-59.
5. 5 Grunden JW, Fisher KA. Lovastatin-induced rhabdomyolysis possibly associated with clarithromycin and azithromycin. Ann Pharmacother 1997; 31: 859-63.
6. 6 Jacobson RH, Wang P, Glueck CJ. Myositis and rhabdomyolysis associated with concurrent use of simvastatin and nefazodone (letter). J Am Med Assoc 1997; 277: 296-97.
7. 7 Lees RS, Lees AM. Rhabdomyolysis from the coadministration of lovaslatin and the antifungal agent itraconazole (letter). N Engl J Med 1995; 333: 664-65.
8. 8 Schmassmann-Suhijar D, Bullingham R, Gasser R, Schmutz J, Haefeli WE. Rhabdomyolysis due to interaction of simvastatin with mibefradil (letter). Lancet 1998; 351: 1929-30.
9. 9 Gabow PA, Kaehny WD, Kelleher SP. The spectrum of rhabdomyolysis. Medicine (Baltimore) 1982; 61: 141-52.
10. 10 Bilheimer DW. Long-term clinical tolerance of lovastatin and simvastatin. Cardiology 1990; 77: 58-65.
11. 11 Walker JF. Simvastatin: the clinical profile. Am J Med 1989; 87: 44-46S.
12. 12 Prueksaritanont T, Gorham LM, Ma B et al. In vitro metabolism of simvastatin in humans [SBT] identification of metabolizing enzymes and effect of the drug on hepatic P450s. Drug Metab Dispos 1997; 25: 1191-99.
13. 13 Wang RW, Kari PH, Lu AY, Thomas PE, Guengerich FP, Vyas KP. Biotransformation of lovastatin. IV. Identification of cytochrome P450 3A proteins as the major enzymes responsible for the oxidative metabolism of lovastatin in rat and human liver microsomes. Arch Biochem Biophys 1991; 290: 355-61.
14. 14 Arnadottir M, Eriksson LO, Thysell H, Karkas JD. Plasma concentration profiles of simvastatin 3-hydroxy-3-methyl-glutaryl-coenzyme A reductase inhibitory activity in kidney transplant recipients with and without ciclosporin. Nephron 1993; 65: 410-13.
15. 15 Neuvonen PJ, Kantola T, Kivisto KT. Simvastatin but not pravastatin is very susceptible to interaction with the CYP3A4 inhibitor itraconazole. Clin Pharmacol Ther 1998; 63: 332-41.
16. 16 Kantola T, Kivisto KT, Neuvonen PJ. Erythromycin and verapamil considerably increase serum simvastatin and simvastatin acid concentrations. Clin Pharmacol Ther 1998; 64: 177-82.
17. + channel. J Biol Chem 1994; 269: 30 707-12.
18. 18 Kaminsky LS, Zhang ZY. Human P450 metabolism of warfarin. Pharmacol Ther 1997; 73: 67-74.
19. 19 Ahmad S. Warfarin therapy (letter; comment). Mayo Clin Proc 1995; 70: 505-506.